Physician profile
Imadeddine Tabbara
NPI 1184794414
$1,227,199.85
in general payments reported to CMS, 2019-2025
60 companies · $50K in 2025
The $50K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342K · 2020: $149K · 2021: $138K · 2022: $245K · 2023: $150K · 2024: $154K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $276K · Travel and Lodging: $46K · Consulting Fee: $20K · Food and Beverage: $11K · Education: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $275,940.00 |
| Travel and Lodging | $46,088.64 |
| Consulting Fee | $20,256.50 |
| Food and Beverage | $10,649.85 |
| Education | $242.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $230,854.35 | 2019-2025 | Iclusig, Alunbrig, Fruzaqla |
| Beigene USA, INC. | $218,299.70 | 2020-2025 | Brukinsa, Tevimbra |
| Celgene Corporation | $148,859.20 | 2019-2025 | Pomalyst, Reblozyl, Opdivo |
| E.R. Squibb & Sons, L.L.C. | $148,233.89 | 2019-2025 | Pomalyst, Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $104,318.26 | 2019-2023 | Imbruvica |
| Genzyme Corporation | $71,597.13 | 2020-2025 | |
| Janssen Biotech, INC. | $56,205.24 | 2019-2025 | Imbruvica, Tecvayli, Rybrevant |
| Amgen INC. | $55,493.10 | 2019-2024 | Kyprolis, Blincyto, Lumakras |
| Glaxosmithkline, LLC. | $35,398.83 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Incyte Corporation | $32,889.04 | 2020-2025 | Monjuvi, Jakafi, Pemazyre |
| Beone Medicines USA, INC. | $18,873.08 | 2025 | Brukinsa, Tevimbra |
| Abbvie INC. | $18,364.45 | 2019-2025 | |
| Genentech USA, INC. | $17,712.95 | 2019-2025 | Polivy, Venclexta, Lunsumio |
| Verastem, INC. | $17,530.52 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $15,167.54 | 2019-2024 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $12,289.89 | 2019-2025 | Gavreto, Tavalisse, Rezlidhia |
| Regeneron Pharmaceuticals, INC. | $8,193.81 | 2024 | |
| Geron Corporation | $5,728.25 | 2025 | Rytelo |
| Servier Pharmaceuticals LLC | $3,248.95 | 2022-2025 | |
| Astellas Pharma US INC | $2,064.40 | 2019-2025 | Cresemba, Vyloy |
| Secura Bio, INC. | $1,980.00 | 2021-2023 | Copiktra |
| Epizyme, INC. | $1,250.00 | 2021 | |
| Beigene, Ltd. | $450.00 | 2020 | |
| Pfizer INC. | $331.58 | 2023-2025 | |
| Daiichi Sankyo INC. | $224.27 | 2024-2025 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $209.88 | 2023-2025 | Libtayo, Lynozyfic |
| Sobi, INC | $197.20 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $98.00 | 2023 | |
| Taiho Oncology, INC. | $85.16 | 2025 | |
| Alexion Pharmaceuticals, INC. | $83.68 | 2024-2025 | Ultomiris |
| Mirati Therapeutics, INC. | $83.41 | 2023-2024 | Krazati |
| Exelixis INC. | $72.06 | 2023-2025 | Cabometyx |
| Adc Therapeutics America, INC. | $63.12 | 2025 | |
| Gilead Sciences, INC. | $58.72 | 2021-2025 | Trodelvy |
| Acrotech Biopharma INC. | $52.51 | 2024-2025 | Beleodaq |
| Astrazeneca Pharmaceuticals Lp | $46.75 | 2023 | |
| Deciphera Pharmaceuticals INC. | $44.59 | 2023-2025 | Qinlock, Romvimza |
| Bayer Healthcare Pharmaceuticals INC. | $36.81 | 2025 | |
| Lilly USA, LLC | $32.76 | 2024 | Verzenio, Jaypirca |
| Pharmaessentia USA Corporation | $32.67 | 2025 | Besremi |
| Emd Serono, INC. | $31.49 | 2024 | |
| Coherus Oncology, INC. | $30.38 | 2025 | Loqtorzi |
| Syndax Pharmaceuticals, INC. | $29.92 | 2025 | |
| Sumitomo Pharma America, INC. | $29.07 | 2025 | Orgovyx |
| Tempus Ai, INC | $28.60 | 2025 | Xt Cdx |
| Ipsen Biopharmaceuticals, INC | $27.83 | 2025 | Onivyde |
| Iovance Biotherapeutics, INC. | $26.42 | 2024 | Amtagvi |
| Novartis Pharmaceuticals Corporation | $26.25 | 2025 | |
| Biocon Biologics INC | $25.89 | 2024 | Ogivri |
| Tersera Therapeutics LLC | $25.24 | 2024 | Xermelo |
| Aveo Pharmaceuticals, INC. | $24.57 | 2023 | Fotivda |
| Eisai INC. | $23.61 | 2025 | |
| G1 Therapeutics, INC. | $21.78 | 2023 | Cosela |
| Eusa Pharma (US) LLC | $21.49 | 2022 | |
| Morphosys, US INC. | $20.44 | 2023 | Monjuvi |
| Sandoz INC. | $19.61 | 2025 | Wyost, Jubbonti |
| Merck Sharp & Dohme LLC | $19.06 | 2025 | Lynparza, Keytruda |
| Karyopharm Therapeutics INC. | $12.45 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imadeddine Tabbara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.